What sermorelin is
Prakash and Goa explain how sermorelin works and what the older studies found.
Read the short review on PubMedUS drug history and compounding
As of September 2026, the drug records show only discontinued sermorelin products; none is marketed with FDA approval.
The US drug agency is called the Food and Drug Administration, abbreviated FDA.
FDA product data: the Orange BookFDA’s March 2013 notice says Geref was not withdrawn because it was unsafe or failed to work. It does not give the maker’s business reason for stopping sales.
Read the Geref (sermorelin) withdrawal findingThe pharmacy rules cover both the ingredient and how the medicine is made. Ask the pharmacy to explain which rules apply to your prescription.
FDA explanation of compounding FDA rules for regular pharmacy ingredients (PDF) FDA ingredient groups for larger sites (PDF)Public licence checks
The medical-board directory points to state boards; the board itself holds the doctor’s licence record.
Find a state medical boardFDA’s pharmacy page points to state pharmacy licence searches.
Start a state pharmacy licence checkOnline visits and testing
The federal guide explains licences across state lines.
The board’s policy explains the care standard for online visits.
Federal telehealth licensing guidance Medical-board telehealth policy (PDF) The board’s guide to newer care models (PDF)What the research tracked
The Corpas and Khorram studies measured hormone responses and other blood results; they do not set a universal testing plan.
Their records are linked with the adult studies below.
The adult studies and their limits
Corpas studied 10 older men over 14 days; Vittone studied 11 men over 6 weeks.
Corpas: hormone levels in older men Vittone: hormone levels and body fatKhorram studied 19 adults over 16 weeks. The medicine copied part of the body’s signal to release growth hormone, a body signal involved in growth. Its building blocks differed from sermorelin’s.
Khorram: findings for a medicine similar to sermorelinThe Khorram study reported no change in sleep quality.
The main childhood growth trial had no comparison group, so it answers a different question from adult care.
Thorner: the childhood growth trialUnwanted effects and urgent symptoms
The sermorelin review reports what people felt in older studies.
The FDA brief reviews CJC-1295, another medicine that prompts growth hormone release. Growth hormone is a body signal involved in growth. The concerns in this brief were not findings from testing sermorelin in adults.
Review of the older sermorelin findings FDA review of CJC-1295 and hormone concerns (PDF)MedlinePlus explains the severe allergic-reaction symptoms that require emergency care.
MedlinePlus: severe allergic reactionsApproval and advertising claims
Use these records to distinguish drug approval, product listing and claims about intended use.
FDA consumer guide to approval claims FDA explanation of National Drug Codes US law: what counts as a drug FTC advice on online health claimsWhich health costs can count
As of September 2026, IRS guidance treats care for a diagnosed disease separately from spending for general health.
IRS guide to medical expenses IRS guide to health savings accountsFor a quoted plan price, return to the service’s written terms and the questions in the cost brief.
Return to the cost briefThe point to carry forward.
Use product records for status, state boards for licences, and matching studies for the proposed result.
Return to the question briefEvidence for this brief
Read the source that matches the claim
A licence record concerns permission to practise. A drug record concerns a product. A study concerns what researchers measured. Keep the question attached to the record.
Open the supporting records